Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
To investigate the predictive value of stathmin expression as a predictive biomarker in OSCC patients, who treated with TPF (docetaxel, cisplatin and 5-fluorouracil ) induction chemotherapy followed by radical surgery and radiotherapy/chemoradiotherapy.
Epistemonikos ID: 2b8bf5aa28f31a4bd16de315f08ff4522f0baad6
First added on: May 21, 2024